Pharma Focus Europe

SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals

Thursday, September 29, 2022

An affiliate of investment firm SK Capital Partners, LP, announced today that it has entered into an agreement to acquire Apotex Pharmaceutical Holdings Inc., a global pharmaceutical company based in Canada. Apotex is recognized for its commitment to producing high-quality and affordable medicines across a wide range of therapeutic areas, benefiting patients worldwide.

SK Capital's Managing Director, Aaron Davenport, expressed enthusiasm about the acquisition, stating, "Apotex is a dynamic and innovative company with a strong track record of success. With our deep experience in the pharmaceutical sector, we are honored to support Apotex as it continues to research, develop, and manufacture safe and affordable medicines for patients across Canada, the United States, and globally."

Jeff Watson, President and CEO of Apotex, shared his excitement about partnering with SK Capital, emphasizing their industry expertise and resources, which will contribute to expanding Apotex's market leadership and ensuring improved access to high-quality and affordable medicines for millions of patients worldwide.

The completion of the transaction is subject to customary regulatory conditions. Leading financial institutions, including RBC Capital Markets, The Bank of Nova Scotia, HSBC, and Truist Securities, are providing committed financing to support the acquisition. RBC Capital Markets, Scotiabank, Jefferies LLC, and Deutsche Bank Securities Inc. acted as financial advisors to SK Capital, while legal counsel was provided by Kirkland & Ellis and McMillan LLP. Rothschild & Co served as the financial advisor to Apotex, with legal counsel provided by Davies Ward Phillips & Vineberg.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva